CHADS2, CHA2DS2ASc, and New ABCD Scores Predict the Risk of Peripheral Arterial Disease in Patients with Sleep Apnea

Figure A1. The cumulative incidences of peripheral arterial disease (PAD) in female subjects (a,b), male subjects (c,d), subjects ≤50 years of age (e,f), and subjects >50 years of age (g,h). The analyses were taken in study arm A (suspected SA vs. control A) (a,c,e,g) and study arm B (probable SA vs. control B) (b,d,f,h). The red continuous lines and blue dashed lines show the cumulative incidence of PAD for the sleep apnea (SA) patients and the control subjects, respectively.

Figure A2. (a) The time-dependent receiver operating characteristic (ROC) curves used to illustrate the performances of scoring systems, including CHADS2, CHA2DS2ASc, and ABCD scores, in predicting subsequent peripheral arterial disease (PAD) in suspected sleep apnea patients. (b) Time-dependent area under the curves (AUCs) and the integrated AUCs. * p < 0.05, pairwise comparison using the method of Uno’s concordance estimation.

Figure A3. (a) The time-dependent receiver operating characteristic (ROC) curves used to illustrate the performances of scoring systems, including CHADS2, CHA2DS2ASc, and ABCD scores, in predicting subsequent peripheral arterial disease (PAD) in probable sleep apnea patients. (b) Time-dependent area under the curves (AUCs) and the integrated AUCs. * p < 0.05, pairwise comparison using the method of Uno’s concordance estimation.

Figure 1. Algorithm for identifying the study population. Abbreviations: SA = sleep apnea; PAD = peripheral arterial disease.

Figure 2. The cumulative incidences of peripheral arterial disease (PAD): The red continuous lines and blue dashed lines show the cumulative incidence of PAD for the sleep apnea (SA) patients and the control subjects, respectively. (a) Study arm A (suspected SA vs. control A); (b) Study arm B (probable SA vs. control B); (c) Study arm PM-A (PM-suspected SA vs. control A-PM); and, (d) Study arm PM-B (PM-probable SA vs. control B-PM).

Figure 3. The incidences of peripheral arterial disease (PAD) in (a,c) suspected sleep apnea (SA) patients and (b,d) probable SA patients. The CHADS2 score was calculated for each subject based on a point system in which one point was assigned for congestive heart failure, hypertension, age ≥75 years, and diabetes mellitus, and two points were assigned for a history of stroke or transient ischemic attack. The CHA2DS2ASc score was calculated for each subject based on a point system, in which one point was assigned for congestive heart failure, hypertension, age of 65–74 years, diabetes mellitus, and female sex, and two points were assigned for age ≥75 years and a history of stroke or transient ischemic attack.

Figure 4. The cumulative incidences of peripheral arterial disease (PAD) in (a,c) suspected sleep apnea (SA) patients and (b,d) probable SA patients. The CHADS2 score was calculated for each subject based on a point system in which one point was assigned for congestive heart failure, hypertension, age ≥75 years, and diabetes mellitus, and two points were assigned for a history of stroke or transient ischemic attack. The CHA2DS2ASc score was calculated for each subject based on a point system, in which one point was assigned for congestive heart failure, hypertension, age of 65–74 years, diabetes mellitus, and female sex, and two points were assigned for age ≥75 years and a history of stroke or transient ischemic attack.

Figure 5. The incidences of peripheral arterial disease (PAD) in (a) suspected sleep apnea (SA) patients and (b) probable SA patients. The ABCD (Age, Blood pressure, Cerebral vascular disease, Diabetes mellitus) score was calculated for each subject based on a point system in which one point was assigned for age >50 years, high blood pressure (hypertension), cerebral vascular disease, and diabetes mellitus, and an extra point was given for age >65 years.